ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Novartis’ SMA therapy gets US priority review
pharmatimes
December 06, 2018US regulators have accepted for review Novartis’ Biologics License Application for Zolgensma, an investigational gene replacement therapy for the treatment of spinal muscular atrophy (SMA) Type 1.
Pharma Sources Insight July 2025
